Cannabinoids, a group of C21 compounds present in Cannabis sativa L., their carboxylic acids, analogs, and transformation products, are the active ingredients found in hasish and marihuana. (-)-trans-D9-tetrahydrocannabinol (D9-THC) is the major psychopharmacologically active component of cannabis. Cannabis affect cognition and memory, euphoria and sedation, and antinociception (analgesia) without the respiratory depression problems associated with opioid analgesics. D9-THC is also immunosuppressive and impairs cell-mediated immunity, humoral immunity and cellular defenses against a variety of infectious agents both in vivo and in vitro. To date, two sub-types of the G-protein coupled cannabinoid receptor, CB1 and CB2, have been identified. The first brain-derived endogenous cannabinoids, an unsaturated fatty-acid ethanolamide, arachidonylethanolamide (AEA, also called anandamide) was found in brain. AEA has higher affinity for the CB1 than for the CB2. Applications: Suitable for use in ELISA. Western Blot, though not tested, may potentially be used as an application. Other applications not tested. Recommended Dilutions: ELISA: 1:10K-100K, using 50-100 ng of THC-BSA or other protein conjugates/well Western Blot: 1-10ug/ml (ECL) Optimal dilutions to be determined by the researcher. Storage and Stability: Lyophilized powder may be stored at -20C. Stable for 12 months at -20C. Reconstitute with sterile ddH2O. Aliquot to avoid repeated freezing and thawing. Store at -20C. Reconstituted product is stable for 12 months at -20C. For maximum recovery of product, centrifuge the original vial after thawing and prior to removing the cap. Further dilutions can be made in assay buffer.
Clonality:
Monoclonal
Clone Designation:
[3H49]
Isotype:
IgG1
Purity:
Purified by Protein A/G affinity chromatography
Form:
Supplied as a lyophilized powder from 10mM Tris-saline buffer, pH 7.5, 0.2% BSA, 0.05% sodium azide. Reconstitute with 100ul sterile ddH2O.
* VAT and and shipping costs not included. Errors and price changes excepted
